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Background: Increasing evidence suggests that inflammation associated with microglial cell activation in the
substantia nigra (SN) of patients with Parkinson disease (PD) is not only a consequence of neuronal degeneration,
but may actively sustain dopaminergic (DA) cell loss over time. We aimed to study whether the intracellular
chaperone heat shock protein 60 (Hsp60) could serve as a signal of CNS injury for activation of microglial cells.
Methods: Hsp60 mRNA expression in the mesencephalon and the striatum of C57/BL6 mice treated with MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and the Hsp60/TH mRNA ratios in the SN of PD patients and
aged-matched subjects were measured. To further investigate a possible link between the neuronal Hsp60 response
and PD-related cellular stress, Hsp60 immunoblot analysis and quantification in cell lysates from SH-SY5Y after
treatment with 100 μM MPP+ (1-methyl-4-phenylpyridinium) at different time points (6, 12, 24 and 48 hours)
compared to control cells were performed. Additional MTT and LDH assay were used. We next addressed the
question as to whether Hsp60 influences the survival of TH+ neurons in mesencephalic neuron-glia cultures treated
either with MPP+ (1 μM), hHsp60 (10 μg/ml) or a combination of both. Finally, we measured IL-1β, IL-6, TNF-α and
NO-release by ELISA in primary microglial cell cultures following treatment with different hHsp60 preparations.
Control cultures were exposed to LPS.
Results: In the mesencephalon and striatum of mice treated with MPTP and also in the SN of PD patients, we
found that Hsp60 mRNA was up-regulated. MPP+, the active metabolite of MPTP, also caused an increased
expression and release of Hsp60 in the human dopaminergic cell line SH-SY5Y. Interestingly, in addition to being
toxic to DA neurons in primary mesencephalic cultures, exogenous Hsp60 aggravated the effects of MPP+. Yet,
although we demonstrated that Hsp60 specifically binds to microglial cells, it failed to stimulate the production of
pro-inflammatory cytokines or NO by these cells.
Conclusions: Overall, our data suggest that Hsp60 is likely to participate in DA cell death in PD but via a
mechanism unrelated to cytokine release.
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Parkinson disease (PD) is a common neurodegenerative
disorder clinically characterized by akinesia, rigidity and
rest tremor [1]. The cardinal neuroanatomical feature of
PD is a massive and preferential loss of dopaminergic
(DA) neurons in the substantia nigra pars compacta
(SNpc) of patients, resulting in a drastic decline in stri-
atal dopamine concentrations.
Another histopathologic hallmark of PD is microglial
activation in the SNpc [2,3]. Activated microglia are be-
lieved to contribute to the neurodegenerative process
through the release of pro-inflammatory and/or cytotoxic
factors such as IL-1β, TNF-α, nitric oxide (NO) and re-
active oxygen intermediates [2]. Moreover, several ob-
servations suggest that an ongoing stimulus could lead
to disease progression long after the initial toxic insult
[4-6], thereby amplifying and sustaining neuroinflam-
mation and, ultimately, leading to destruction of nigral
DA neurons. These processes are generally considered
to be a non-specific consequence of neuronal death. But
the possibility that suffering/damaged DA neurons might
also participate in the activation of microglia and in sus-
taining neuroinflammation deserves consideration.
In light of our knowledge about the innate immune
system, it is highly plausible to assume that Toll-like re-
ceptors (TLRs) are major mediators in glial cells triggering
the release of cytokines that ultimately kill DA neurons in
the SNpc. Accordingly, as first demonstration in the cen-
tral nervous system (CNS), the only cellular population
that stained positive for Toll-like receptor 4 (TLR4) in the
brain parenchyma of adult rats were microglia [7].
Traditionally, it has been considered that the danger-
associated molecules sensed by TLRs are highly con-
served, so called pathogen-associated molecular patterns
(PAMPs), which are expressed by bacteria, viruses, or
other pathogens but are not present in mammalian
cells [8]. For example, bacterial lipopeptides (BLPs),
lipopolysaccharide (LPS), and flagellins are recognized
by TLR2, TLR4, and TLR5, respectively. A number of
reports have emerged to suggest that diverse molecules
of host-cell origin may also serve as endogenous li-
gands of TLR2 or TLR4 [9]. To date, there have been
at least 23 reports of distinct endogenous ligands of
TLR2 or TLR4, representing molecules of diverse
source and structure, ranging from those associated
with cell damage and major extracellular matrix (ECM)
turnover to inflammatory mediators and oxidatively
modified lipids [10].
Recently, we have demonstrated that TLR4-deficient
mice are less vulnerable to MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) intoxication than wild-type
mice and display a decreased number of Iba1+ and
MHC II+ activated microglial cells after MPTP applica-
tion, suggesting that the TLR4 pathway is involved inexperimental PD. However, the TLR4 ligand responsible
for this activation remains elusive [7].
Neuronal activators of the TLR4-dependent pathway in
microglia could be heat shock proteins (Hsps), a group of
highly conserved proteins that are constitutively expressed
in most cells under physiological conditions. They are
commonly induced by the presence of denatured proteins
and contribute to the restoration of the tertiary structure
and enzymatic activity of these proteins [11]. Upon cellu-
lar stress, Hsps are up-regulated and released from suffer-
ing/damaged cells [12,13]. Beside the assumption that the
Hsp response to cell injury plays a beneficial role in cell
survival, recent evidence suggests that Hsps can also exert
immunomodulatory functions [14]. Hsp60 - which is typ-
ically located in mitochondria, a primary subcellular
pathogenic locus in PD [15] - was found to be aberrantly
expressed on the cell surface of neuronal cells in response
to stress [16,17]. Interestingly, Hsp60 binds to microglia
and the microglial receptor for Hsp60 has been suggested
to be TLR4 [18]. In addition, a recent study demonstrated
that Hsp60 serves as an endogenous signal of injury in the
CNS by activating microglia via a TLR4- and myeloid dif-
ferentiation factor 88 (MyD88)-dependent pathway [19].
This mechanism may account for the triggering of inflam-
matory responses in the vicinity of suffering/damaged DA
neurons and engage a neuronal-glial crosstalk. We there-
fore investigated the role of Hsp60 in this scenario which
may be released or expressed at the cell surface of suffer-
ing/damaged DA neurons and contribute to their demise.
Material and methods
Animals and MPTP treatment
Adult (eight to ten weeks) male C57/BL6 mice (Janvier
Breeding Centre, France) were housed, handled, and cared
for in accordance with the Guide for the Care and Use of
Laboratory Animals (NCR (National Research Council)
1996) and the European Union Council Directive 86/609/
EEC, and the experimental protocols were carried out in
compliance with institutional ethical committee guidelines
for animal research. For all studies, mice were maintained
on a 12:12 hour light/dark cycle with lights on at 6.30 am.
The room temperature was kept at 23°C, with free access
to standard diet (LASQCdiet® Rod16-R, LASvendi) and
tap water. Mice (n = 8 to 10 per group) were treated using
the acute MPTP paradigm (4 × 20 mg/kg MPTP-HCl
(Sigma-Aldrich, Lyon, France) every 2 hours) [20,21] and
animals were sacrificed after 12, 24, 48, 96 or 168 hours
after the last injection. The brain was excised and the spe-
cific brain regions dissected. The corresponding controls
were collected variously across the days.
Hsp60 mRNA-PCR in the striatum and SN of mice
Striatum and SN of the mice were dissected. Tissues
were then placed into Trizol reagent (Invitrogen, Cergy
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was prepared according to the manufacturer’s instruc-
tions. First-strand cDNA was synthesized from 1 μg of
total RNA using the ThermoScript RT-PCR system
(Invitrogen, Cergy Pontoise Cedex, France). To access
expression levels specific designed intron-spanning
primers for Hsp60 (fwd = 5′-CAC AGT GAA GGA
TGG AAA AAC CCT-3′ and rev = 5′-TCT TTG GTG
ACA ATG ACC TCC C-3′) and tubulin (fwd = 5′-TGT
CCA TGA AGG AGG TGG ATG AG-3′ and rev = 5′-
ATG TTG CTC TCA GCC TCG GTG AAC-3′) were
used. The annealing temperature was 64°C and the
number of PCR cycles was chosen to stop the reaction
in the linear phase of amplification (25 cycles). The
amplification of Hsp60 and tubulin was done in the
same reaction for each sample. After gel electrophor-
esis, digital images were analyzed with NIH ImageJ soft-
ware for quantification.Hsp60 qRT-PCR of human SN
The Hsp60 and TH primers for quantitative PCR were
designed by primer express 3.0 (Applied Biosystems,
Darmstadt, Germany) and their specificity was confirmed
by blastn analysis. Their sequences were as followed:
Hsp60_fwd: 5′-GCC GCC CCG CAG AA-3′, Hsp60_rev:
5′-CCT GGA CAC CGG TCT CAT CT-3′, TH_fwd: 5′-
GCA CCT TCG CGC AGT TCT-3′, TH_rev: 5′-ACA
GCG TGG ACA GCT TCT CA-3′. Mesencephalon ss
PD patients and age-matched control subjects (n = 5 per
group) were provided by the INSERM UMR_S1127
brain bank. The SN was dissected from frozen slides.
Total RNA was extracted with Trizol (Invitrogen, Cergy
Pontoise Cedex, France) and the quantity and quality
were determined by Nanodrop and Agilent, respectively.
One microgram of total RNA was reverse-transcribed with
Superscript III RT-kit (Invitrogen, Cergy Pontoise Cedex,
France) according to the manufacturer’s instructions.
qPCR was performed with SYBR GreenER TM qPCR
SuperMix kit (Invitrogen, Cergy Pontoise Cedex, France)
in ABI 7500 real time thermal cycler (Applied Biosystems,
Darmstadt, Germany). The relative mRNA expression
levels were normalized by the geometric mean of two
housekeeping genes (GAPDH and HPRT) with qBaseplus
software (Primerdesign, Southampton, UK).SH-SY5Y cell cultures
SH-SY5Y (p3-p7) cells [22] were maintained in DMEM
(Gibco, Saint Aubin, France) supplemented with 15% FCS,
1 mM L-glutamine, 100 U of penicillin/ml, and 100 μg of
streptomycin sulfate/ml and equilibrated with 5% CO2-
95% air at 37°C. At different time points, the cells were
treated with 100 μM MPP+ (1-methyl-4-phenylpyridi-
nium) [23] purchased from Sigma-Aldrich (Lyon, France).Primary mesencephalic cell cultures
Mesencephalic cultures were prepared from the ventral
midbrain of Swiss mouse embryos at gestational age
13.5 days (Janvier Breeding Center, France). The dissected
tissue pieces were processed according to previously de-
scribed protocols [24,25]. Briefly, after mechanical dissoci-
ation in modified L15 medium [26] with no enzymatic
treatment, the cells in suspension were plated at a density
of 1.5 to 2.0 × 105 cells/cm2 in polyethylenimine (PEI,
Sigma-Aldrich, Lyon, France; 1 mg/mL) precoated culture
plates (24 well-plates). The cells were then allowed to ma-
ture and differentiate in N5 culture medium [25,27], sup-
plemented with 5% horse serum and 0.5% fetal calf serum
(FCS, endotoxin level of the used FCS < 10 EU/ml) except
for the first three days in vitro (DIV), when the concentra-
tion of FCS was raised to 2.5% to favor cell attachment
and initial development. Mesencephalic DA neurons de-
generate spontaneously and progressively when main-
tained in N5 culture medium supplemented with serum
proteins, whereas other types of neurons survive. The
death of these neurons occurs spontaneously through a
mechanism that is dependent on glial cells [24,28]. It
could be shown previously that depolarization by elevation
of extracellular K+ ([K+] 30 mM) was efficient in prevent-
ing DA cell demise. Note that K+-induced depolarization
was performed in the presence of 1 μM MK-801 to pre-
vent secondary excitotoxic stress. In some experiments,
Ara-C (2 μM) was added to the medium at DIV 1 to 2
after plating to inhibit proliferation of non-neuronal cells
(astrocytes, microglia) as well in the presence of 1 μM
MK-801 to prevent secondary excitotoxic stress [28].
Mesencephalic cultures were treated either with 1 μM
MPP+ at DIV 4 and DIV 5 as previously described [29],
10 μg/ml low-endotoxin recombinant human Hsp60 dis-
solved in PBS (hHsp60; Loke Diagnostics ApS, Risskov,
Denmark) at DIV 2 to DIV 5 or in combination of both.
The hHsp60 contained < 2 endotoxic units of LPS/mg of
protein as determined by limulus amoebocyte lysate assay
(BioWhittaker, Cologne, Germany). Since hHsp60 has a
much weaker effect than MPP+ on cell death, we decide to
prolonged treatment of the cell cultures compared to
MPP+ treatment. At DIV 5, medium including MPP+ and
hHsp60 was removed and cultures were left to recover
until DIV 10 in control medium. Trypsin proteolysis
(Gibco, Saint Aubin, France) or pre-treatment by boil-
ing of hHsp60 were used to control for Hsp60-mediated
effects, as well as additional treatment with polymyxin
B (10 μg/ml, PMBS, Sigma-Aldrich, Lyon, France) as a
specific LPS inhibitor to control for LPS effects.
Highly enriched microglial cultures of mice ventral
mesencephalon
Almost pure microglial cultures were obtained using a
technique of high-yield isolation of microglia by mild
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cultures were prepared as described previously except
for the culture medium, which was DMEM/F12 nutrient
mixture (DMEM/F12; Invitrogen, Cergy Pontoise, France)
supplemented with 10% FCS (endotoxin level of the used
FCS < 10 EU/ml). After DIV 14, the cultures were washed
for 1 minute with DMEM/F12 to eliminate serum and
then incubated with a trypsin/EDTA solution (0.25% tryp-
sin, 1 mm EDTA in HBSS; Invitrogen, Cergy Pontoise,
France) diluted 1:4 in DMEM/F12 for half to one hour at
37°C until the upper layer (mainly constituted by neurons/
astrocytes) was detached. The medium containing the
layer of detached cells was aspirated and the highly
enriched microglial cell population (98% of pure microglial
cells) that remained attached to the bottom of the well
was exposed to 500 μl of DMEM/F12 with 10% FCS to
allow trypsin inactivation. The cells were treated with low-
endotoxin recombinant human Hsp60 (hHsp60) 10 μg/ml
and contained < 2 endotoxic units of LPS/mg of pro-
tein as determined by limulus amoebocyte lysate assay
(BioWhittaker, Cologne, Germany) or LPS 0.1 μg/ml
(Sigma-Aldrich, Lyon, France, strain 055:B5), both dis-
solved in PBS.
MTT and LDH assays
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazo-
lium bromide, Sigma-Aldrich, Lyon, France) was added
to the cells at a final concentration of 0.25 mg/ml and
incubated for 1 hour [31-33]. Thereafter, the cells were
lysed and quantified using a microplate reader (Multi-
skanReader, ThermoLabsystems, Egelsbach, Germany) at
a wavelength of 570 nm. Cell death and cell lysis was
based on lactate dehydrogenase (LDH) activity released
into the supernatant. LDH activity was measured using
the CytoTox 96® Non-Radioactive Cytotoxicity Assay
(Promega, Lyon, France) according to the manufacturer’s
protocol.
Western blots
For Western blotting, cellular protein was isolated using
the lysis buffer M-PER Mammalian Protein Extraction Re-
agent according to the manual (Pierce, Perbio, Brebières,
France). Twenty micrograms total protein/lane was loaded
onto a reducing 12% SDS-PAGE and electroblotted onto
nitrocellulose membranes. After blotting, the internal pro-
tein loading controls were prepared according to the man-
ual of MEM Code, Pierce (Perbio, Brebières, France).
Afterwards, the membranes were blocked and incubated
for 24 hours at 4˚C with a monoclonal mouse anti-Hsp60
antibody (0.5 μg/ml; R&D Systems,Wiesbaden, Germany)
and for the loading control with an anti-beta-actin poly-
clonal rabbit antibody (1:2,000, Sigma-Aldrich, Lyon,
France), respectively. For detection, the nitrocellulose
membranes were washed and incubated with a HRP-conjugated secondary antibody (Jackson ImmunoRe-
search, West Grove, PA, USA; goat-anti-mouse or goat-
anti-rabbit both 1:50,000). After AB-incubation membranes
were incubated in Super Signal Ultra substrate working
solution (Perbio, Brebières, France) and exposed to an
autoradiographic film (Mat Plus DG Film, Kodak, Maisons-
Alfort, France). Afterwards, Western blot signals were
analyzed by densitometry using the NIH Image software
Scion, and the Hsp60/α-actin ratio was calculated.
Immunocytochemical procedures in vitro
All cell cultures were fixed for 15 minutes at room
temperature with formaldehyde (4% in PBS) and washed
three times with PBS. For primary mesencephalic cell
cultures, the survival of DA neurons was determined by
tyrosine hydroxylase (TH) immunocytochemistry. The
cultures exposed first for 24 hours at 4°C to a rabbit-
polyclonal anti-TH antibody (Pel-Freez Biologicals, Rogers,
AR, USA) diluted 1:1,000 in PBS containing 0.2% Triton
X-100, were then incubated for one hour at room tem-
perature with an anti-rabbit IgG Alexa488 conjugate (1:500;
Sigma-Aldrich/RBI, Lyon, France). In order to identify the
total number of neurons in the cultures, cultures were in-
cubated for 48 hours at 4°C with a mouse anti-neuronal
Nuclei (NeuN) biotin conjugated monoclonal antibody
(Chemicon International, Limburg, Germany) and then in-
cubated with a streptavidin-Cy3-antibody (1:1,000, Jackson
ImmunoResearch, West Grove, PA, USA) for 1 hour at
room temperature. Mesencephalic cultures contained
between 1 and 3% TH+ cells at the time of plating. To
quantify the cells, the entire TH+ and/or NeuN+ neurons
of the used wells were counted.
In the primary microglial cultures, microglial cells
were identified with a rat anti-CD11b Ig (MAC-1; Serotec,
Oxfordshire, UK; 1:100 in PBS, 24 hours at 4°C) and re-
vealed using an anti-rabbit IgG Alexa488 conjugate (1:500;
Sigma-Aldrich/RBI, Lyon, France). Note that Triton X-100
was not used for the detection of microglial cell surface
markers. A polyclonal rabbit beta-tubulin antibody was
used (Cell Signaling, Leiden, Netherlands; 1: 200 in PBS
containing 0.2% Triton X-100, 24 hours at 4°C) to detect
cytoskeletal structures and revealed using an anti-rabbit
IgG Alexa488 conjugate (1:500; Sigma-Aldrich/RBI, Lyon,
France).
For staining double-stranded DNA, we used PBS con-
taining 10 μg/ml 4’6-diamidino-2-phenylindole (DAPI,
Sigma-Aldrich, Lyon, France). Illustrations of microglial
cells are presented as inverted images. For the confocal
images, a Leica SP1 confocal microscope was used (Leica,
Wetzlar, Germany).
Hsp60 binding studies
For binding studies, labeled or unlabeled hHsp60 and BSA
(Sigma-Aldrich, Lyon, France) were used. The labeled
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labeling kits from Molecular Probes, Saint Aubin,
France, according to the manufacturer’s protocol. For
binding of hHsp60 to primary microglia 1 × 106 cells were
incubated on ice with either 10 μg/ml Alexa 647-labeled
hHsp60 or BSA. To exclude an unspecific effect of labeled
proteins, cells were also treated with unlabeled proteins
(hHsp60 or BSA). Cells that obtained unlabeled hHsp60
were treated with 30 μl of Cohn II fraction (Sigma-
Aldrich, Lyon, France) and stained with Hsp60-specific
antibody (clone LK-1, 1:100 in PBS), TRITC-labeled goat
anti-mouse secondary antibody (1:400 in PBS) and DAPI
(1:1,000 in PBS). After staining cells were fixed in PBS/1%
paraformaldehyde (PFA), centrifuged onto glass slides, and
covered with anti-FADE solution (BiomedDia, Zweibruechen,
Germany).
Hsp60 quantification
The estimation of protein concentration was performed
by the Bradford assay and verified by SDS-PAGE followed
by silver staining. Western blot for Hsp60 quantification
was made with a specific anti-Hsp60 monoclonal antibody
(SPA-810, StressGen, San Diego, CA, USA).
FACS staining
1 to 2 × 106 microglial cells were washed with PBS, de-
tached and incubated with different concentrations of
hHsp60 (1 to 50 μg/ml) on ice for 30 minutes. Cells
were washed with PBS and Fc receptors of cells were
blocked with 30 μl of Cohn II fraction (10 mg/ml,
Sigma-Aldrich, Lyon, France) prior to staining with a
specific antibody against Hsp60 (SPA-810; StressGen,
San Diego, CA, USA). To avoid an internalization of cell
surface-bound Hsp60, the incubation of microglial cells
with Hsp60 was done on ice. Cells were then washed and
a phycoerythrin-labeled goat-anti mouse IgG (Jackson
ImmunoResearch, West Grove, PA, USA) was added.
Cytokine and Hsp60 quantification by ELISA
The supernatant of SH-SY5Y cell cultures was collected
at different time points, centrifuged and immediately
frozen at −80°C. The detection of Hsp60 was carried out
by using a quantitative sandwich immunoassay (Hsp60-
ELISA-Kit, StressGen, San Diego, CA, USA) according
to the manufacturer’s protocol. Release of microglial cy-
tokines (IL-1β, IL-6 and TNF-α) was measured at differ-
ent time points (1, 2, 4, 6 and 24 hours) after addition of
10 μg/ml hHsp60.
In addition, microglial cells were treated with hHsp60
that was left untreated, boiled, trypsin-inactivated or
pre-incubated with either a specific Hsp60-antibody
(Clone 4B9; Dianova, Hamburg, Germany) or an isotypic
IgG2-antibody (Santa Cruz Biotechnology Inc., Heidelberg,
Germany). As a positive control for cytokine release,primary microglial cells were incubated with only LPS
(0.1 μg/ml), a prototypical inflammogen known to acti-
vate microglia through TLR4 stimulation [34,35].
Cytokine release into the supernatant was measured
employing the DuoSet ELISA Development System mouse
IL-1β, IL-6 and TNF-α (R&D Systems, Wiesbaden,
Germany). ELISAs were performed according to the
manufacturer’s protocol.
Measurement of NO
Accumulated nitrite, a stable oxidation product of NO,
was measured using Griess reagents [36]. Fifty microliters
of primary microglial cell supernatants were transferred
to a 96-well microtiter plate and 50 μl of solution 1 (1%
sulfanilamide in 5% phosphoric acid) were added. After
10 minutes incubation in the dark, 50 μl of solution 2
(0.1% naphthylethylenediamine dihydrochloride) were
added and incubated for 10 more minutes in the dark. The
absorbance was measured at 450 nm using a plate reader
(ELISA-Reader Infinite® 200 series, Tecan, Crailsheim,
Germany).
Statistical analysis
All in vitro experiments were performed in at least three
independent experiments, with a minimum of three wells
per experimental condition. We confirm that there is no
duplication of data presentation in the text. Data are
expressed as the percent of corresponding control values.
The normalization to control was used because of the high
variance due to the different preparations of primary
cell cultures. Each data point represents mean ± SEM.
Multiple comparisons against a single reference group
were performed by one-way analysis of variance
(ANOVA) followed by a post hoc Dunnett’s test. When
all pairwise comparisons were carried out, one-way ANOVA
was followed by a post hoc Student-Newman-Keuls test.
For the human qPCR experiments, a Spearman correl-
ation test between Hsp60 and TH mRNA expression
was calculated. The null hypothesis was rejected at an α
risk of 5%.
Results
Hsp60 mRNA up-regulation is observed in MPTP-treated
mice and in PD patients
We postulated that injury of DA neurons could result in
the release of Hsp60, causing activation of microglia cells.
To test this hypothesis, we first examined the dynamic
changes of Hsp60 mRNA expression in the mesen-
cephalon and the striatum of C57/Bl6 mice intoxicated
with MPTP. Compared to saline-treated animals, Hsp60
mRNA expression was up-regulated in the mesencephalon
and striatum of MPTP-exposed mice, the striatal response
being more sustained in time (Figure 1A). Thus, this sug-
gests that MPTP-induced mitochondrial stress in nigral
Figure 1 Hsp60 mRNA expression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice and Parkinson disease (PD)
patients. (A) Hsp60 mRNA expression in the mesencephalon (substantia nigra (SN), filled circles) and the striatum (open circles) of C57/BL6 mice
treated with MPTP. Mice (n = 8 to 10 per group) were treated using the acute MPTP paradigm (4 × 20 mg/kg MPTP-HCl (Sigma-Aldrich, Lyon,
France) every 2 hours) and animals were killed 12, 24, 48, 96 or 168 hours after the last injection. (B) Hsp60/TH mRNA ratios in the SN of PD
patients and aged-matched subjects. Results were expressed as a ratio to correct for dopaminergic (DA) cell loss in PD. *P < 0.05 versus
corresponding controls.
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confront these results with the human pathology, we fur-
ther assessed the expression level of Hsp60 transcripts in
human post-mortem SN specimen by qRT-PCR. We found
a significant increase in the Hsp60/TH ratio (to correct
for DA cell loss in PD) in PD patients (n = 5) compared to
age-matched control subjects (n = 5) (Figure 1B) suggest-
ing that the Hsp60 stress response may play a role in the
pathomechanism of PD.
Mitochondrial stress induces up-regulation and release of
Hsp60 in the human dopaminergic cell line SH-SY5Y
To further investigate a possible link between the neur-
onal Hsp60 response and PD-related cellular stress, we
treated the human DA cell line SH-SY5Y with the mito-
chondrial toxin MPP+ and first assessed Hsp60 expression.
As shown in Figure 2A, exposure of DA cells to MPP+
induced a time-dependent up-regulation of Hsp60 ex-
pression as assayed by immunoblot analysis on whole
cell lysates. Up-regulation was first noticed 12 hours after
intoxication and continuously increased up to 48 hours.
The level of Hsp60 was not only increased in the intracel-
lular compartment but also in the cell culture supernatant
(Figure 2B), suggesting that cellular damage induced by
mitochondrial alteration can stimulate the release ofstress-related factors from diseased DA neurons. Im-
portantly, increased extracellular Hsp60 observed at 12
and 48 hours following MPP+ treatment was not due to
permeabilization of cell membranes as the release of
LDH (a determinant of cell membrane integrity) was
only significant after 24 hours of treatment (Figure 2C).
By contrast, decreased mitochondrial cell function evi-
denced via the MTT assay [37] was detected earlier (six
hours) after MPP+ treatment and concomitant with the
rise in extracellular Hsp60. Altogether, these results indi-
cate that MPP+ treatment of SH-SY5Y cells compromised
their function and stimulated the release of Hsp60 well
before membrane rupture and death, suggesting the ex-
istence of an active Hsp60 secretory mechanism when
DA neurons are in a suffering/damaged state.
Hsp60-induced glial cell activation, mediates DA cell
death and exacerbates MPP+ toxicity in mesencephalic
cultures
We next addressed the question whether Hsp60 influences
neuronal cell death and treated primary mesencephalic
cultures with either 1 μM MPP+ at DIV 4 and DIV 5,
10 μg/ml hHsp60 at DIV 2 to 5, or a combination of
both. At DIV 5, medium including MPP+ and hHsp60
was removed and cultures were left to recover until
Figure 2 Hsp60 induction and release after MPP+ treatment. (A) Hsp60 immunoblot analysis and quantification in cell lysates from SH-SY5Y
after treatment with 100 μM MPP+ (at 6, 12, 24 and 48 hours) compared to control cells. (B) Hsp60 released by cultured SH-SY5Y cells treated by
MPP+ (100 μM, at 6, 12, 24 and 48 hours) compared to control cultures. (C) MTT and lactate dehydrogenase (LDH) assay in SH-SY5Y cells exposed
to MPP+ (100 μM, at 6, 12, 24 and 48 hours) compared to control cells. MTT assay (black bars), LDH assay (grey bars). *P < 0.05 versus
corresponding controls.
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conditions, hHsp60 treatment decreased TH+ neurons
to 68.3% ± 2.6% compared to untreated cultures and the
overall population of neurons (NeuN+ cells) of these cul-
tures to 74.4% ± 0.7% (Figure 3A). Treatment with MPP+
decreased the number of TH+ cells to 50.3% ± 1.4%, but didFigure 3 Induction of dopaminergic (DA) cell death by Hsp60. (A) Sur
either with MPP+ (1 μM), hHsp60 (10 μg/ml) or a combination of both. (B)
to native hHsp60 (10 μg/ml) alone or in the presence of thelipopolysaccha
also applied to AraC (2 μM)-treated cultures, a treatment that eliminates m
corresponding controls. #P < 0.05 versus hHsp60 treatment.not affect the number of NeuN+ cells (98.6% ± 0.7%). Pri-
mary mesencephalic cultures contain only 1 to 3% of DA
neurons (TH+) [38]. These neurons are selectively killed by
MPP+ at the dosage used, leaving intact the remaining
neuronal populations. Thus, the number of NeuN+ positive
neurons was not significantly affected by MPP+ treatment.vival of TH+ neurons in mesencephalic neuron-glia cultures treated
Survival of TH+ neurons in mesencephalic neuron-glia cultures exposed
ride antagonist PMBS (10 μg/ml), or to trypsinized hHsp60. hHsp60 was
ost of glial cells from mesencephalic cultures. *P < 0.05 versus
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to a further loss of TH+ neurons in comparison to MPP+
or hHsp60 treatment alone (MPP+: 50.3% ± 1.4%, hHsp60:
68.3% ± 2.6 co-treatment of MPP+/hHsp60: 29.4% ± 1.3%),
but exerted no additional effect on NeuN+ cells (co-
treatment of MPP+/hHsp60: 73.6% ± 1.3%, MPP+: 98.6% ±
0.7%, hHsp60: 74.4% ± 0.7%) (Figure 3A).
To determine whether neuronal cell death mediated
by Hsp60 required glial cell activation, we inhibited the
proliferation of glial cells with the anti-mitotic agent
AraC (2 μM) applied at DIV 1 for 48 hours [28]. The
elimination of glial cells from the cultures curtailed
neuronal cell death induced by Hsp60 (Figure 3B). Be-
sides, hHsp60-dependent neurotoxic effects were almost
abrogated when hHsp60 was previously denatured by
trypsinization (TH+: 94.3% ± 1.2%), but not when cul-
tures were exposed to both hHsp60 and the specific LPS
antagonist PMBS (TH+: 66.3% ± 2.1%), suggesting that the
effects of hHsp60 occurred by a mechanism unrelated to
that elicited by LPS (Figure 3B).
Hsp60 binds to microglia but does not induce
pro-inflammatory cytokine release
A direct biological effect of Hsp60 on microglia requires
the binding to specific receptors. Therefore, to determine
whether Hsp60 could provoke microglial cell-activating
properties similar to those previously reported for mac-
rophages [39,40], we performed in vitro stimulation of
primary microglial cell cultures with recombinant hHsp60.
For comparative purposes, control cultures were ex-
posed to LPS. Since Hsp60 is thought to induce a pro-
inflammatory response through binding to the LPS
receptor TLR4 [41], we first analyzed the binding prop-
erties of hHsp60 on murine microglia. Incubation of
microglial cells with Alexa647-conjugated hHsp60, but
not with Alexa647-conjugated BSA used as a negative
control, revealed a punctuated distribution of bound
hHsp60 suggesting the presence of cell surface recep-
tors that binds to the protein (Figure 4A). Fluorescence-
activated cell sorting (FACS) analysis of cells incubated
with increasing concentrations of hHsp60 indicated a
non linear and saturable binding of hHsp60 to microglia,
thus further supporting the view that microglial cells
express specific Hsp60 receptors (Figure 4B).
Subsequently, microglial cells were treated with hHsp60
at a concentration of 10 μg/ml. After 1, 2, 4, 6 and
24 hours respectively, hHsp60-exposed cells showed no
morphological alterations (that is enlargement of cell
bodies; data not shown). Furthermore, they did not release
significantly increased amounts of pro-inflammatory cyto-
kines (IL-6, IL-1β and TNF-α) or NO compared to the
control condition (Figure 4C). In the LPS-treated positive
control (0.1 μg/ml), significant values of IL-6 and TNF-α
could be shown after 6 and 24 hours respectively for NO.However, a significant increase of IL-1β could not be
shown in the LPS-treated group. This may be due to con-
centrations of LPS used being too low and/or the time of
measurement being too early (six hours) to sufficiently
stimulate IL-1β release.
In addition, microglial cells were exposed to different
hHsp60 preparations (native hHsp60, hHsp60 denatured
by trypsinization or boiling and hHsp60 pre-incubated
with Hsp60-specific antibody or isotype control antibody).
After 12 and 24 hours respectively, hHsp60-exposed
cells did not release significantly increased amounts of
pro-inflammatory cytokines (IL-6 and TNF-α) compared
to the control condition. (Figure 4D). Taken together,
these observations strongly suggest that microglia express
cell surface receptors to interact with Hsp60. Microglia,
however, do not react to Hsp60 with the production of
measurable amounts of classical pro-inflammatory cyto-
kines such as IL-1β, IL-6, TNF-α or NO release.
Discussion
Experimental data presented here suggest that Hsp60
might participate actively in DA cell demise in PD. First,
in vivo, we observed that Hsp60-mRNA was up-regulated
in the mouse mesencephalon and striatum in a toxin-
based model of PD, as well as in the SN of PD patients.
Second, in vitro, we showed that MPP+ increases the ex-
pression and release of Hsp60 from DA cells and exacer-
bates MPP+-induced DA cell death. Surprisingly, however,
despite this specific binding to microglia already been
shown by Lehnardt et al. [19], hHsp60 did not cause in-
duction of pro-inflammatory cytokines.
Hsps were initially discovered as participants in the
cellular response to stress [42]. Other studies suggested
that self and microbial Hsps may also play an important
role in the control of the immune response [43]. In par-
ticular, Hsps including Hsp60, Hsp70 and gp96 released
by injured or dying cells, are believed to function as en-
dogenous danger signals to the immune system indicating
tissue injury [44-47]. Here, we evaluated the potential role
of Hsp60 in DA cell demise in PD, a pathological condi-
tion in which inflammatory processes are thought to con-
tribute actively to degeneration.
Using the acute MPTP mouse model, characterized by a
robust gliosis in the SNpc with significant up-regulation of
inducible NOS and activation of microglia [48], we dem-
onstrated that Hsp60 mRNA expression is up-regulated in
the mesencephalon and the striatum after MPTP intoxi-
cation, suggesting that Hsp60 had the potential to oper-
ate as an endogenous activator of microglia in animal
models of PD. Supporting this view, the kinetics of Hsp60
up-regulation after MPTP intoxication resembled that of
CD11b/Mac1 induction which reflects microglial activa-
tion [48]. Interestingly, we found that in the SN of PD
patients, Hsp60 mRNA also up-regulated compared to
Figure 4 Hsp60 and inflammatory processes mediated by microglial cells. (A) Left: microglial cells exposed to Alexa647-conjugated hHsp60
(red label) or Alexa647-conjugated BSA (used as negative control) with 4’6-diamidino-2-phenylindole (DAPI) (blue label) counterstaining of cell
nuclei. Scale bar = 50 μm. Right: confocal laser scanning microscopy of microglial cells that were exposed to Alexa647-conjugated Hsp60 (red
label), then stained with an α-tubulin antibody (green label) and counterstained with DAPI (blue label). Scale bar = 10 μm. (B) Measure of cell
surface binding of hHsp60 using extracellular FACS analysis of microglial cells labeled with an anti-Hsp60 monoclonal antibody (SPA-810,
StressGen, San Diego, CA, USA) and a phycoerythrin-labeled secondary antibody. (C) Microglial cells were treated with hHsp60 at a concentration
of 10 μg/ml, after 1, 2, 4, 6 and 24 hours respectively. Lipopolysaccharide (LPS) treatment for 6 hours for cytokine release respectively 24 hours for
nitric oxide (NO)-release in a concentration of 0.1 μg/ml was used as positive control. (D) In addition, microglial cells were exposed to different
hHsp60 preparations (native hHsp60, hHsp60 denatured by trypsinization or boiling and hHsp60 pre-incubated with Hsp60-specific antibody or
isotype control antibody), after 12 and 24 hours, respectively. lipopolysaccharide (LPS) treatment for 12 hours in a concentration of 0.1 μg/ml was
used as positive control, PBS as buffer control.
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with the MPTP mouse model might be of relevance for
the human pathology.
The assumption that Hsp60 could intervene actively
in the progression of the disease was also supported by
several observations made in two complementary cell
culture settings; (i) we found that mitochondrial stress
triggered by MPP+ caused an up-regulation and release
of Hsp60 in human DA SH-SY5Y cells well before the
onset of neuronal cell demise; in our model system, the
release of Hsp60 was already detectable in the super-
natant of cells with intact plasma membranes, so that
cell lysis would not be necessary for the accumulation
of Hsp60 in the extracellular milieu, (ii) application of
Hsp60 to primary mesencephalic cultures triggered DA
cell death per se and importantly, it also exacerbated the
toxicity of MPP+ for these neurons.The stimulation of TLR4 by LPS induces the release of
critical pro-inflammatory cytokines that are necessary to
activate potent immune responses. Recently, we could
demonstrate that TLR4-deficient mice are less vulnerable
to MPTP intoxication than wild-type mice and display a
decreased number of activated microglial cells after MPTP
application, suggesting that the TLR4 pathway is involved
in experimental PD. However, the endogenous activator of
TLR4 in this scenario could not be identified [49]. A num-
ber of arguments suggested that Hsp60 could be a poten-
tial ligand for TLR4, which is expressed on microglia,
astrocytes and endothelial cells in the central nervous sys-
tem [50-53]. In particular, extracellular eukaryotic Hsp60
was found to induce the release of pro-inflammatory cyto-
kines such as IL-1, IL-6, IL-12, and TNF-α in dendritic
cells and macrophages [43,45,54,55]. Lehnardt et al. deter-
mined in a previous study that the neurotoxic effect of
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Lehnardt et al. could show that microglia bind Hsp60-
Alexa, whereas neurons, oligodendrocytes and astrocytes
did not show any labeling with Hsp60-Alexa [19]. There-
fore, we have placed the focus in our study on microglia
and not on astrocytes or endothelial cells.
Here, we observed an induction of Hsp60 after MPTP
intoxication. Furthermore, we established that Hsp60 binds
specifically to microglia in a saturable-dependent manner,
suggesting that the protein could operate as an endogen-
ous activator of TLR4, thus stimulating inflammatory pro-
cesses. In contrast to the latter, Hsp60 did not induce the
release of detectable amounts of cytokines. However, low
levels of pro-inflammatory cytokines that are below detec-
tion limit may be induced by Hsp60 and might well exert
biological activity in a certain microenvironment: that is
the direct contact of microglia with neighbouring neuronal
cells. In addition, Hsp60 may induce the production of
stimulatory or toxic molecules other than IL-1β, IL-6,
TNF-α or NO that were not analyzed in this study.
Taking into consideration that Hsp60 activates murine
antigen-presenting cells (APC) also via TLR4 independ-
ent pathways in the absence of LPS or other so called
pathogen-associated molecular patterns (PAMPs) [41,56],
it is also possible that the Hsp60 acts via other receptors
such as the lectin-like oxidized low-density lipoprotein
receptor-1 (LOX-1) previously identified as a putative re-
ceptor for Hsp60 in microglial cells [57]. Other PAMP
could be involved in the stimulation of the innate immune
system in some types of sterile inflammation, like PD,
which need to be explored in further studies.
Alternatively, a direct effect of Hsp60 on DA neurons
remains also conceivable. Yet, the requirement of glial
cells in the effects of Hsp60 appeared crucial as its toxic
effects towards DA neurons were curtailed in neuronal-
enriched cultures.
Conclusions
Taken together, we could demonstrate a deleterious role
of Hsp60 on DA neurons in different experimental PD
models. However, our data do not support that Hsp60 is
an endogenous activator of the TLR4-pathway in experi-
mental PD models and, by extrapolation, in the human
disease. Thus the cellular target of Hsp60 remains to be
identified.
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